Breaking News on Contract Research, Manufacturing & Clinical Trials

On the road > Oncology News

News in brief

GSK taps NCCN for cancer drug trials


GSK has awarded the National Comprehensive Cancer Network (NCCN) grants worth $4m to support trials involving ofatumumab and pazopanib.

The NCCN, a not-for-profit network of 21 US cancer research centres, said it would be testing the drugs as treatment for hematologic malignancies and solid tumors, respectively.

Jeffery Bloss, GSK’s VP of oncology drug development, said the funding “will help expand the research and knowledge base of GSK Oncology’s newer cancer therapies.”

The two pharmaceuticals, branded as Arzerra and Votrient, are already approved by the US Food and Drug Administration (FDA) and generated around £13m (€15.5m) each last year according to GSK’s annual results.

Related suppliers

Key Industry Events


Access all events listing

Our events, Shows & Conferences...